Odevixibat: Targeting IBAT to Transform Cholestatic Liver Disease Treatment

　　Odevixibat(Bylvay)is a groundbreaking oral small molecule targeting ileal bile acid transporter(IBAT).By selectively inhibiting IBAT,it disrupts enterohepatic bile acid cycling,enhancing fecal excretion and reducing systemic bile acid toxicity.This innovative approach revolutionizes care for patients with severe cholestatic disorders.

　　Key Features：

　　1.Mechanism&Indications：

　　○Inhibits intestinal IBAT to limit bile acid reabsorption→lowers serum bile acids→alleviates hepatotoxicity and pruritus.

　　○Approved for:

　　•PFIC(all types)in patients≥3 years old.

　　•Cholestatic manifestations of Alagille Syndrome.

　　2.Global Availability&Pricing Insights：

　　○Not yet approved in Greater China;access via international markets:

　　■Original(Bylvay):Approx.US$6,500 for 4.5mg×30 capsules(prices vary).

　　■Generic equivalents:Approx.US$70(same spec),offering affordable alternatives.

　　3.Dosing Protocol：

　　○Initial dose:40μg/kg once daily(max 120μg/kg based on tolerance).

　　○Fixed dose for adults>40kg:5mg/day.

　　○Administer with/without food;swallow capsules whole.Missed doses should not be compensated.

　　4.Safety Profile&Precautions：

　　•Common AEs:Diarrhea(80%),abdominal pain,nausea,fat malabsorption,vitamin deficiencies(A/D/E/K).

　　•Contraindications:Hypersensitivity,Child-Pugh C liver failure,bile duct obstruction.

　　•Special populations:

　　○Mild-moderate liver impairment:No dose adjustment required(monitor closely).

　　○Pregnancy/Lactation:Use with caution due to limited data.

　　○Pediatrics:Weight-based dosing with growth monitoring.

　　5.Therapeutic Management：

　　○Regular monitoring:Bile acids,LFTs,bilirubin,vitamins,growth parameters(pediatric).

　　○Long-term therapy essential;discontinue only if unresponsive or intolerant.

　　○Drug interactions:Administer≥4 hours apart from bile acid sequestrants(e.g.,cholestyramine).